Vulvar cancer breakthrough: surgery tailored by virus and gene status
NCT ID NCT05576831
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to see if matching the extent of surgery to the specific type of vulvar cancer (based on HPV infection and p53 gene changes) can reduce the chance of the cancer coming back. About 249 women with early-stage vulvar squamous cell carcinoma will take part. The goal is to move away from a one-size-fits-all approach and offer more personalized treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VULVAR CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
BC Cancer - Vancouver Centre
RECRUITINGVancouver, British Columbia, V5Z 2E6, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- New imaging tool could help surgeons detect hidden cancer cells during surgery
- New drug combo targets HPV-Driven cancers in phase II trial
- Two-Drug combo aims to shrink vulvar tumors before surgery
- New study aims to uncover why some women have worse sexual side effects from radiation
- Question list may empower gynecologic cancer patients in clinic